The FDA is trying to take away your thyroid meds
Are you taking a Natural Desiccated Thyroid (NDT) medication like Armour®, NP Thyroid®, or a compounded version? Then you need to pay attention to this.
The FDA has been attempting to reclassify NDT as a “biologic.” This move would shift it into the same complex category as vaccines, insulin, and monoclonal antibodies.
Why should this concern you as a thyroid patient?
This reclassification isn't about safety; NDT has been used effectively for over a century. Instead, it’s about control. This change could create significant hurdles for manufacturers and compounding pharmacists, potentially restricting your access to the medication that works best for you.
It could lead to:
🔹 Less choice in your treatment options.
🔹 Higher costs for your medication.
🔹 Difficulty getting prescriptions filled.
As the video explains, this is a move toward consolidating power and creating monopolies, taking medical freedom away from patients and their doctors. Many people with hypothyroidism and Hashimoto's thrive on NDT because it provides a full spectrum of thyroid hormones (T4, T3, T2, T1, and calcitonin) that synthetic options like levothyroxine don't.
Your ability to choose the right path for your health is crucial. Don't let regulatory changes limit your access to effective treatment.
Have you had success with NDT? Share your story in the comments.
#ThyroidHealth #Hypothyroidism #Hashimotos #NDT #ArmourThyroid
Natural Desiccated Thyroid (NDT) medications have been a cornerstone for many patients managing hypothyroidism and Hashimoto's thyroiditis due to their comprehensive hormone spectrum, including T4, T3, T2, T1, and calcitonin. Unlike synthetic thyroid replacements such as levothyroxine, NDT offers bioidentical hormones sourced from porcine thyroid glands, which some patients find more effective in minimizing symptoms. The FDA’s recent push to reclassify NDT as a “biologic” places it alongside complex biologics like vaccines, insulin, and monoclonal antibodies. This classification brings about a stricter regulatory pathway intended for biologics, which could drastically increase manufacturing costs, regulatory compliance burdens, and create barriers for compounding pharmacists who produce customized versions of NDT. These challenges threaten to reduce the availability of these medications and limit patient access. This shift is less about medication safety—NDT medications have been used for over a century without major safety concerns—and more about consolidating pharmaceutical control and creating monopolies in the thyroid medication market. Restricting access could lead to fewer treatment options, higher prices, and difficulties for patients and healthcare providers in obtaining prescriptions. It is vital for thyroid patients and advocates to stay informed about these regulatory developments and engage with policymakers to protect medical freedom. Patients thriving on NDT should document their experiences and consider communicating with healthcare providers and support groups. The reclassification underscores the need for transparent healthcare policies that balance safety with patient choice and accessibility. To safeguard your thyroid treatment, actively participate in discussions on thyroid health, and explore resources on NDT hormone therapy options. Sharing stories and raising awareness can contribute to preserving access to these life-changing medications amid evolving regulations.
